KR20190056436A - Fxr 작용제로서의 이속사졸 유사체 및 그의 사용 방법 - Google Patents

Fxr 작용제로서의 이속사졸 유사체 및 그의 사용 방법 Download PDF

Info

Publication number
KR20190056436A
KR20190056436A KR1020197012682A KR20197012682A KR20190056436A KR 20190056436 A KR20190056436 A KR 20190056436A KR 1020197012682 A KR1020197012682 A KR 1020197012682A KR 20197012682 A KR20197012682 A KR 20197012682A KR 20190056436 A KR20190056436 A KR 20190056436A
Authority
KR
South Korea
Prior art keywords
optionally substituted
compound
group
cycloalkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020197012682A
Other languages
English (en)
Korean (ko)
Inventor
준 마
구오지앙 왕
빈 왕
슈에차오 싱
루이차오 센
징 헤
야트 선 오
Original Assignee
이난타 파마슈티칼스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이난타 파마슈티칼스, 인코포레이티드 filed Critical 이난타 파마슈티칼스, 인코포레이티드
Publication of KR20190056436A publication Critical patent/KR20190056436A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197012682A 2016-10-04 2017-10-04 Fxr 작용제로서의 이속사졸 유사체 및 그의 사용 방법 Withdrawn KR20190056436A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662404059P 2016-10-04 2016-10-04
US62/404,059 2016-10-04
PCT/US2017/055147 WO2018067704A1 (en) 2016-10-04 2017-10-04 Isoxazole analogs as fxr agonists and methods of use thereof

Publications (1)

Publication Number Publication Date
KR20190056436A true KR20190056436A (ko) 2019-05-24

Family

ID=61830059

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197012682A Withdrawn KR20190056436A (ko) 2016-10-04 2017-10-04 Fxr 작용제로서의 이속사졸 유사체 및 그의 사용 방법

Country Status (13)

Country Link
US (2) US10450306B2 (enExample)
EP (1) EP3523298A4 (enExample)
JP (1) JP2019537557A (enExample)
KR (1) KR20190056436A (enExample)
CN (1) CN109906223A (enExample)
AU (1) AU2017338853A1 (enExample)
BR (1) BR112019006651A2 (enExample)
CA (1) CA3039124A1 (enExample)
IL (1) IL265803A (enExample)
MX (1) MX2019003790A (enExample)
PH (1) PH12019550050A1 (enExample)
RU (1) RU2019113066A (enExample)
WO (1) WO2018067704A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190071801A (ko) * 2016-11-04 2019-06-24 헤파진 테라퓨틱스, 인크. Fxr 조절제로서의 질소-함유 복소환식 화합물

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
MX379579B (es) 2015-03-31 2025-03-11 Enanta Pharm Inc Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para su uso.
US10080743B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017189652A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10080742B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10149835B2 (en) 2016-05-18 2018-12-11 Elmore Patent Law Group, P.C. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017201152A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
EP3468962A1 (en) 2016-06-13 2019-04-17 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
US10450306B2 (en) 2016-10-04 2019-10-22 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
US10597391B2 (en) 2016-10-26 2020-03-24 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
EP4424364A3 (en) 2017-03-28 2024-11-27 Gilead Sciences, Inc. Methods of treating liver disease
WO2019118571A1 (en) 2017-12-12 2019-06-20 Enanta Pharmaceuticals, Inc. Isoxazole analogs as fxr agonists and methods of use thereof
CN110128432B (zh) 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
US10829486B2 (en) 2018-02-14 2020-11-10 Enanta Pharmacueticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2020011146A1 (zh) * 2018-07-11 2020-01-16 中国医药研究开发中心有限公司 1,2,4-噁二唑类化合物及其制备方法和医药用途
WO2020029908A1 (zh) * 2018-08-08 2020-02-13 广州市恒诺康医药科技有限公司 螺桥环化合物、其药物组合物及其用途
CN112805279B (zh) * 2018-12-07 2023-09-12 四川科伦博泰生物医药股份有限公司 异噁唑衍生物及其制备方法和用途
AU2020209564B2 (en) 2019-01-15 2022-12-01 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
CN112955448B (zh) * 2019-01-31 2023-02-03 中国医药研究开发中心有限公司 芳环或芳杂环类化合物及其制备方法和医药用途
CN118388474A (zh) 2019-02-19 2024-07-26 吉利德科学公司 Fxr激动剂的固体形式
CN111825595A (zh) * 2019-04-15 2020-10-27 山东轩竹医药科技有限公司 钠通道阻滞剂
BR112021020681A2 (pt) 2019-04-19 2021-12-07 Shanghai Inst Materia Medica Cas Agonista de molécula pequena de fxr e método de preparação para o mesmo e uso do mesmo
WO2020231917A1 (en) 2019-05-13 2020-11-19 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
KR20220035365A (ko) 2019-07-18 2022-03-22 엔요 파마 인터페론의 부작용을 감소시키는 방법
JP2022541503A (ja) 2019-07-23 2022-09-26 ノバルティス アーゲー Ｆｘｒアゴニストを使用した肝疾患の組み合わせ処置
TW202114671A (zh) 2019-07-23 2021-04-16 瑞士商諾華公司 包含fxr促效劑之治療
JP7663559B2 (ja) 2019-09-03 2025-04-16 ノバルティス アーゲー Ａｃｔｒｉｉ受容体拮抗薬を含む肝疾患または肝臓障害の治療
WO2021053618A1 (en) 2019-09-19 2021-03-25 Novartis Ag Treatment comprising fxr agonists
WO2021064575A1 (en) 2019-09-30 2021-04-08 Novartis Ag Treatment comprising the use of fxr agonists
CN110804025B (zh) * 2019-11-29 2022-02-08 扬州工业职业技术学院 一种卤代苯异噁唑衍生物及其制备方法与应用
KR20220119424A (ko) 2019-12-20 2022-08-29 노파르티스 아게 인테그린 억제제를 사용한 간 질환의 조합 치료
CN114945361A (zh) 2020-01-15 2022-08-26 法国国家卫生及研究医学协会 Fxr激动剂在治疗丁型肝炎病毒感染中的用途
TW202208355A (zh) 2020-05-04 2022-03-01 美商安進公司 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
CU20220065A7 (es) 2020-05-04 2023-06-13 Amgen Inc Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
CN114195786B (zh) * 2020-09-18 2023-08-22 凯思凯迪（上海）医药科技有限公司 新型fxr小分子激动剂制备及其用途
CN114315830B (zh) * 2020-09-30 2025-08-12 中国科学院上海药物研究所 Fxr小分子激动剂及其制备方法和用途
US20220112178A1 (en) * 2020-10-14 2022-04-14 Tosk, Inc. Small Molecule Modulators of RAS GTPase
US12180220B2 (en) 2020-10-14 2024-12-31 Tosk, Inc. Heteroaryl modulators of RAS GTPase
WO2022101853A1 (en) 2020-11-16 2022-05-19 Novartis Ag Method of determining liver fibrosis
EP4247793A1 (en) * 2020-11-17 2023-09-27 H. Lundbeck A/S New catecholamine prodrugs for use in the treatment of parkinson's disease
AU2022209084A1 (en) 2021-01-14 2023-08-10 Centre Leon Bérard Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
CN113024552B (zh) * 2021-03-26 2022-08-05 厦门市博瑞来医药科技有限公司 一类新型非甾体fxr激动剂的合成及其应用
WO2022229302A1 (en) 2021-04-28 2022-11-03 Enyo Pharma Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment
CN115433175B (zh) * 2021-06-02 2025-05-27 上海交通大学 一类含炔基取代的喹啉和喹唑啉类化合物及其制备和用途
CN118742306A (zh) * 2022-01-17 2024-10-01 和博医药有限公司 苯并噻唑-哌嗪基-噁唑化合物的固体形式及其使用方法

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571809A (en) 1989-04-20 1996-11-05 Boehringer Ingelheim Pharmaceuticals, Inc. The treatment of HIV-1 infection using certain pyridodiazepines
ES2326850T3 (es) 1998-12-23 2009-10-20 Glaxo Group Limited Ensayos para ligandos de receptores nucleares.
EP2062583B1 (en) 1999-04-30 2012-12-26 The Regents of the University of Michigan Therapeutic applications of pro-apoptotic benzodiazepines
AU2002308295B2 (en) 2001-03-12 2007-08-23 Intercept Pharmaceuticals, Inc. Steroids as agonists for FXR
EP1285914B1 (en) 2001-08-13 2007-12-19 PheneX Pharmaceuticals AG Nr1h4 nuclear receptor binding compounds
EP1539697A1 (en) * 2002-07-19 2005-06-15 Memory Pharmaceutical Corporation Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
WO2004046162A2 (en) 2002-11-14 2004-06-03 The Scripps Research Institute Non-steroidal fxr agonists
US7319109B2 (en) 2002-11-22 2008-01-15 Smith Kline Beecham Corporation Farnesoid X receptor agonists
US20070054902A1 (en) 2003-12-02 2007-03-08 Shionogi & Co., Ltd. Isoxazole derivatives as peroxisome proliferator-activated receptors agonists
ATE526318T1 (de) 2005-12-19 2011-10-15 Glaxosmithkline Llc Farnesoid-x-rezeptor-agonisten
KR20080110998A (ko) * 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Ｊａｋ­２ 조절자로서 ４­아릴­２­아미노­피리미딘 또는 4­아릴­２­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
CN101421250A (zh) * 2006-01-30 2009-04-29 埃克塞里艾克西斯公司 作为jak-2调节剂的4-芳基-2-氨基-嘧啶或4-芳基-2-氨基烷基-嘧啶及包含它们的药物组合物
CN101374834B (zh) * 2006-02-03 2011-12-14 伊莱利利公司 用于调节fxr的化合物和方法
DK2029547T3 (da) 2006-05-24 2010-07-26 Lilly Co Eli FXR-agonister
TW200811170A (en) 2006-06-27 2008-03-01 Sanofi Aventis Urea derivatives of tropane, their preparation and their therapeutic application
TWI404718B (zh) * 2006-08-15 2013-08-11 Novartis Ag 調節硬脂醯CoA去飽和酶活性之化合物及其用途
EP1894928A1 (en) 2006-08-29 2008-03-05 PheneX Pharmaceuticals AG Heterocyclic fxr binding compounds
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
EP2069177A4 (en) 2006-09-15 2012-12-05 Volvo Lastvagnar Ab METHOD FOR ADAPTING AN AUTOMATIC MECHANICAL BOX ON A HEAVYWEIGHT VEHICLE
CL2007003035A1 (es) 2006-10-24 2008-05-16 Smithkline Beechman Corp Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
EP1918281A1 (en) * 2006-11-02 2008-05-07 Laboratorios del Dr. Esteve S.A. Phenylamino-substituted piperidine compounds, their preparation and use as medicaments
JP2010513458A (ja) * 2006-12-19 2010-04-30 ファイザー・プロダクツ・インク Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用
MX2009009849A (es) * 2007-03-15 2009-09-24 Schering Corp Derivados de piridazinona sustituida con piperazina utiles como inhibidores de glucano sintasa.
CN101977505A (zh) * 2007-06-13 2011-02-16 葛兰素史密丝克莱恩有限责任公司 类法尼醇x受体激动剂
KR20100044810A (ko) 2007-07-02 2010-04-30 글락소스미스클라인 엘엘씨 파네소이드 ｘ 수용체 효능제
TW200906823A (en) * 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
US20090163474A1 (en) 2007-10-19 2009-06-25 Wyeth FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases
EP2110374A1 (en) * 2008-04-18 2009-10-21 Merck Sante Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators
EP2128158A1 (en) 2008-05-26 2009-12-02 Phenex Pharmaceuticals AG Heterocyclic cyclopropyl-substituted FXR binding compounds
TW201022266A (en) 2008-10-23 2010-06-16 Boehringer Ingelheim Int Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
US8329904B2 (en) 2009-05-12 2012-12-11 Hoffmann-La Roche Inc. Azacyclic derivatives
WO2011021645A1 (ja) 2009-08-19 2011-02-24 大日本住友製薬株式会社 ２環性ウレア誘導体、またはその薬学的に許容される塩
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
HUE026967T2 (en) 2009-11-05 2016-07-28 Glaxosmithkline Llc Benzodiazepine Bromodomain inhibitor
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
EP2655368A1 (en) * 2010-12-20 2013-10-30 Irm Llc Compositions and methods for modulating farnesoid x receptors
JP2014500319A (ja) 2010-12-20 2014-01-09 アイアールエム・リミテッド・ライアビリティ・カンパニー ファルネソイドｘ受容体を調節するための組成物および方法
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
AU2013256362A1 (en) 2012-05-01 2014-11-13 Catabasis Pharmaceuticals, Inc. Fatty acid conjugates of statin and FXR agonists: compositions and methods of use
DK3043865T3 (da) 2013-09-11 2021-02-01 Univ Claude Bernard Lyon Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion
HK1243930A1 (zh) 2014-11-06 2018-07-27 英安塔制药有限公司 作爲fxr/tgr5激动剂的胆汁酸类似物和其使用方法
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
EP3034501A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
JP2017537960A (ja) 2014-12-18 2017-12-21 ノバルティス アーゲー 肝疾患および胃腸疾患の治療に使用するためのｆｘｒアゴニストとしてのアザビシクロオクタン誘導体
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
CN106946867B (zh) 2016-01-06 2019-11-12 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和用途
WO2017128896A1 (zh) 2016-01-26 2017-08-03 江苏豪森药业集团有限公司 Fxr激动剂及其制备方法和应用
CN106995416A (zh) 2016-01-26 2017-08-01 上海翰森生物医药科技有限公司 Fxr激动剂及其制备方法和应用
CN107021957A (zh) 2016-02-01 2017-08-08 山东轩竹医药科技有限公司 Fxr受体激动剂
WO2017133521A1 (zh) 2016-02-01 2017-08-10 山东轩竹医药科技有限公司 Fxr受体激动剂
RU2743075C2 (ru) 2016-02-22 2021-02-15 Новартис Аг Способы применения агонистов fxr
WO2017189652A1 (en) 2016-04-26 2017-11-02 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10080743B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10080742B2 (en) 2016-04-26 2018-09-25 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
US10149835B2 (en) 2016-05-18 2018-12-11 Elmore Patent Law Group, P.C. Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017201152A1 (en) 2016-05-18 2017-11-23 Enanta Pharmaceuticals, Inc. Isoxazole derivatives as fxr agonists and methods of use thereof
US10144729B2 (en) 2016-05-18 2018-12-04 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
AR108711A1 (es) 2016-06-13 2018-09-19 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4)
EP3468962A1 (en) 2016-06-13 2019-04-17 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
TW201808283A (zh) 2016-08-05 2018-03-16 廣東東陽光藥業有限公司 含氮三環化合物及其在藥物中的應用
EP3954684A1 (en) 2016-08-23 2022-02-16 Ardelyx, Inc. Process for the preparation of hormone receptor modulators for treating metabolic conditions and disorders
US10450306B2 (en) 2016-10-04 2019-10-22 Enanta Pharmaceuticals, Inc. Isoxazole analogs as FXR agonists and methods of use thereof
CN107973790A (zh) 2016-10-22 2018-05-01 合帕吉恩治疗公司 杂环fxr调节剂
US10597391B2 (en) 2016-10-26 2020-03-24 Enanta Pharmaceuticals, Inc. Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof
CN108017636A (zh) 2016-11-04 2018-05-11 合帕吉恩治疗公司 作为fxr调节剂的含氮杂环化合物
CN106588804B (zh) 2016-12-09 2018-11-09 都创(上海)医药科技有限公司 一种作为类法尼醇x受体(fxr)的化合物的制备方法
CN106632294A (zh) 2016-12-15 2017-05-10 宁波百纳西药业有限公司 一种螺环化合物及其药物用途
CN109071468B (zh) 2017-01-20 2022-09-02 四川科伦博泰生物医药股份有限公司 一种杂环化合物及其制备方法和用途
CN108341822B (zh) 2017-01-23 2021-04-16 广州市恒诺康医药科技有限公司 Fxr受体调节剂及其制备方法和应用
WO2018170173A1 (en) 2017-03-15 2018-09-20 Metacrine, Inc. Farnesoid x receptor agonists and uses thereof
WO2018190643A1 (en) 2017-04-12 2018-10-18 Il Dong Pharmaceutical Co., Ltd. An isoxazole derivatives as nuclear receptor agonists and used thereof
CN110662743B (zh) 2017-05-26 2022-09-30 石药集团中奇制药技术（石家庄）有限公司 作为fxr受体激动剂的内酰胺类化合物
JP6997870B2 (ja) 2017-07-06 2022-02-10 シュアンチュー バイオファーマシューティカル カンパニー，リミティド Ｆｘｒ受容体刺激薬
US10829486B2 (en) 2018-02-14 2020-11-10 Enanta Pharmacueticals, Inc. Isoxazole derivatives as FXR agonists and methods of use thereof
CN109053751A (zh) 2018-08-30 2018-12-21 成都海博锐药业有限公司 具有螺环结构的fxr调节剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190071801A (ko) * 2016-11-04 2019-06-24 헤파진 테라퓨틱스, 인크. Fxr 조절제로서의 질소-함유 복소환식 화합물

Also Published As

Publication number Publication date
WO2018067704A1 (en) 2018-04-12
US20180099957A1 (en) 2018-04-12
MX2019003790A (es) 2019-09-26
US10450306B2 (en) 2019-10-22
IL265803A (en) 2019-06-30
AU2017338853A1 (en) 2019-04-18
CA3039124A1 (en) 2018-04-12
PH12019550050A1 (en) 2019-07-24
EP3523298A1 (en) 2019-08-14
US20200079764A1 (en) 2020-03-12
RU2019113066A (ru) 2020-11-09
CN109906223A (zh) 2019-06-18
US11034684B2 (en) 2021-06-15
JP2019537557A (ja) 2019-12-26
BR112019006651A2 (pt) 2019-07-02
EP3523298A4 (en) 2020-06-24

Similar Documents

Publication Publication Date Title
KR20190056436A (ko) Fxr 작용제로서의 이속사졸 유사체 및 그의 사용 방법
WO2018081285A1 (en) Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
KR20230069090A (ko) 항바이러스제로서의 기능화된 펩타이드
WO2017201152A1 (en) Isoxazole derivatives as fxr agonists and methods of use thereof
JP2019513129A (ja) Ｂ型肝炎抗ウイルス剤
WO2017201155A1 (en) lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
CN107231795A (zh) 作为fxr/tgr5激动剂的胆汁酸类似物及其使用方法
WO2017189652A1 (en) Isoxazole derivatives as fxr agonists and methods of use thereof
JP2017533923A (ja) Ｆｘｒ／ｔｇｒ５アゴニストとしての胆汁酸類似体およびその使用方法
WO2017189663A1 (en) Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017189651A1 (en) Isoxazole derivatives as fxr agonists and methods of use thereof
WO2017201150A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
TW202321251A (zh) 新穎螺環吡咯啶衍生的抗病毒劑
JP7328254B2 (ja) アポトーシスシグナル調節キナーゼ１阻害剤を含むテトラゾール及びその使用方法
KR20170133339A (ko) Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
US10689391B2 (en) Isoxazole analogs as FXR agonists and methods of use thereof
WO2019160813A1 (en) Isoxazole derivatives as fxr agonists and methods of use thereof
CA2961033A1 (en) Heterocyclic compound
JP2019535777A (ja) スルホニル尿素胆汁酸誘導体の調製方法
CA2598861A1 (en) Organic compounds
JP2024534799A (ja) １７－ベータ－ヒドロキシステロイドデヒドロゲナーゼ１３型阻害剤及びその使用方法
WO2020041417A1 (en) Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
AU2006236622A1 (en) Compositions of novel opioid compounds and method of use thereof
CN116440127A (zh) 一种多肽衍生物及其抗病毒用途
CA3063180A1 (en) Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000